L-Nutra is a nutri-tech company specializing in healthspan and longevity through nutrition science, primarily offering the Fasting Mimicking Diet (FMD)—a plant-based program that nourishes the body while mimicking fasting effects to promote cellular rejuvenation, metabolic reset, and healthy aging.[1][4] It serves healthcare, wellness, nutrition sectors, and individuals managing conditions like type 2 diabetes, pre-diabetes, and weight loss, with products like Prolon® Next Gen and L-Nutra Health programs that deliver results such as 22lb average weight loss, 1.4% A1C reduction, and 59% reduced insulin resistance.[1][3] Backed by over 37 clinical trials, 210 patents, and collaborations with 18 global universities, L-Nutra advances "Nutrition for Longevity" and "Nutrition as Medicine," positioning itself as a leader in turning sick care into health care.[1][4]
The company also operates Nutritech Therapeutics, its biotech arm developing plant-based therapeutics using FMD technology to target life-threatening diseases via autophagy and cellular repair, offering an upstream intervention alternative to traditional pharmaceuticals.[2]
L-Nutra traces its roots to breakthroughs in fasting research by founder Valter Longo, Ph.D., a pioneer with 30 years in longevity and healthy nutrition, directing the Longevity Institute at USC and the Longevity and Cancer Program at IFOM in Italy.[4] The idea emerged from Longo's discoveries on periodic fasting's benefits for slowing biological aging—termed "juventology"—and making it safer via Fasting Mimicking Technology, supported by NIH grants and SBA funding.[4]
Incorporated in 2021 (with operations from 2013), the company is headquartered in Plano, Texas, and led by CEO Joseph Antoun, alongside executives like CFO Michael Wolfe.[1][5] Early traction came from developing the FMD platform, clinically tested for healthspan benefits, evolving into consumer products like Prolon and disease-specific programs.[1][4]
L-Nutra rides the longevity and nutri-tech wave, capitalizing on rising demand for healthspan extension amid aging populations and chronic disease epidemics like diabetes.[1][3] Its timing aligns with advances in autophagy research and personalized nutrition, amplified by post-pandemic wellness focus and GLP-1 alternatives seeking sustainable, natural options.[3] Market forces favoring plant-based, evidence-driven interventions—backed by NIH/SBA funding—position it against pharma giants by intervening upstream via diet, potentially reducing healthcare costs (e.g., $10K savings per patient).[1][3][4]
It influences the ecosystem by pioneering "Nutrition as Medicine," inspiring clinical adoption of FMD and bridging consumer wellness with biotech therapeutics, challenging traditional sick care models.[2][4]
L-Nutra is poised to expand Prolon Next Gen globally and scale Nutritech Therapeutics' disease-specific mimetics, leveraging its patent portfolio for partnerships or pharma licensing.[1][2] Trends like AI-driven nutrition personalization, rising longevity investing, and metabolic health demands will propel growth, especially as clinical data mounts. Its influence may evolve from niche diets to mainstream therapeutics, widening the biological-chronological age gap and reshaping preventive health—fulfilling its mission to make age-related diseases relics of the past.[4]
L Nutra has raised $47.0M in total across 1 funding round.
L Nutra's investors include Flagship Ventures, Kima Ventures.
L Nutra has raised $47.0M across 1 funding round. Most recently, it raised $47.0M Series D in November 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2023 | $47.0M Series D | Flagship Ventures, Kima Ventures |
